ERD-308 |
Katalog-Nr.GC36001 |
ERD-308 ist ein hochwirksamer von Hippel-Lindau-basierter PROTAC-Degrader des Östrogenrezeptors (ER) fÜr die Behandlung von ER-positivem Brustkrebs. ERD-308 induziert >95 % des ER-Abbaus bei so niedrigen Konzentrationen wie 5 nM in beiden Zelllinien (DC50 (Konzentration, die 50 % des Proteinabbaus verursacht) von 0,17 nM und 0,43 nM in MCF-7- und T47D-ER+-Zellen , beziehungsweise).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2320561-35-9
Sample solution is provided at 25 µL, 10mM.
ERD-308 is a highly potent PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively)[1]. DC50: 0.17 nM (ER in MCF-7 cells), 0.43 nM (ER in T47D ER+ cells)[1].
[1]. Hu J, et al. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). J Med Chem. 2019 Feb 14;62(3):1420-1442.
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *